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Abstract 
 
Immune checkpoint blockade has demonstrated great potential in activating antitumor immunity.  
Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte antigen-4.  CTLA-4 
belongs to the CD28 class of receptors and is found on the surface of CD4+ and CD8+ T cells.  
CTLA-4 acts to suppress the immune system when bound to CD80 and CD86 receptors on 
antigen presenting cells.  Ipilimumab, or anti-CTLA-4, has shown to be effective in significantly 
extending the survival of patients with metastatic melanoma.  However, systemic delivery of 
Ipilimumab also induces significant side effects such as: colitis, dermatitis, uveitis, and 
hypophysitis.  In order to minimize toxicity, we and others have hypothesized that intratumoral 
administration of anti-CTLA-4 at a lower dose can have the same antitumor efficacy as systemic 
delivery but without the toxicity.  This work begins with an investigational pilot study to 
determine the efficacy of anti-CTLA-4 by delivering 60 µg of anti-CTLA-4 to a group of mice 
and measuring the tumor growths when compared to an untreated control group.  Once efficacy 
had been demonstrated, a dosing study was conducted to identify an optimal intratumoral dosage 
delivered to murine models.  The groups were given doses of either 30 µg, 60 µg, or 120 µg.  
From this study, the 60 µg group had the lowest average tumor size of 300 mm3.  Our lab has 
previously demonstrated that IL-12 co-formulated with chitosan has demonstrated prolonged 
intratumoral retention therefore, 60 µg of anti-CTLA-4 was co-formulated with a chitosan 
solution to investigate the efficacy in a delivery vehicle.  Finally, 60 µg of anti-CTLA-4 was 
delivered in a proprietary hydrogel alone and with Interleukin-12 to examine the effects of 
controlled release. 
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1. Introduction 
A mutation in the sequence of DNA in a gene can lead a cell to become cancerous.  Cancer can 
be quickly summarized as uncontrolled cell division.  This cell division that occurs in a 
cancerous cell will lead to the development of a solid tumor within the body.  Definitively curing 
this disease has proved troublesome as scientists have attempted surgery, radiation, and 
chemotherapy as the main treatment routes for patients.  Currently, cancer trails only 
cardiovascular disease as the largest cause of death among individuals in the world1.  Pancreatic 
cancer has a mortality rate near 85%.  In addition to being characterized as one of the most 
aggressive cancers, about 44,000 new cases of pancreatic cancer are diagnosed every year.  
Pancreatic cancer has a 5 year survival rate of less than 5% while the median time of patient 
survival after diagnosis barely reaches six months.  Pancreatic cancer is highly metastatic and 
resistant to drug treatments which helps to explain the poor survival rate2,3. 
 
Recently, a new method of cancer treatment has emerged in the form of immune checkpoint 
inhibitors.  This treatment utilizes the machinery found in the immune system to attack and 
destroy cancer cells.  Anti-CTLA-4 is a monoclonal antibody which targets cytotoxic T-
lymphocyte antigen-4.  Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an immunoglobulin 
protein found on the surface of CD4+ and CD8+ T cells and is part of the CD28 class of protein 
receptors.  CTLA-4 delivers an inhibitory signal to T cells when bound to CD80 and CD86 
expressed on antigen presenting cells.  Anti-CTLA-4, or Ipilimumab, is an immune checkpoint 
inhibitor currently approved to treat metastatic melanoma. By blocking this interaction, anti-
CTLA-4 essentially eliminates the ability of CTLA-4 to send inhibitory signals to T cells and 
thus activates T cell function4,5.  Yet, anti-CTLA-4 therapy has shown to induce severe 
autoimmune effects in patients such as colitis, dermatitis, uveitis, and hypophysitis making 
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effective delivery of dosage and treatment difficult in clinical trials4,5.  In clinical trials for 
Ipilimumab, Bristol Myers Squibb released a Phase III trial that showed improved life 
expectancy of over six hundred patients diagnosed with metastatic melanoma.  Ipilimumab was 
given at 3 mg/kg early on during investigation only to show little efficacy, however, reevaluation 
at 10mg/kg of Ipilimumab systemic delivery with immune factors showed an increased survival 
by over 2 months, a significant increase5.  Sandin et al. locally delivered anti-CTLA-4 to 
pancreatic tumors in murine models and have demonstrated that lower dose peritumoral 
injections of the antibody performed similar to that of the standard method of treatment of anti-
CTLA-4 by higher dose systemic delivery5.  In a paper published by Fransen et al., a slow 
release delivery system of Montanide ISA-51 was delivered with anti-CTLA-4 subcutaneously in 
murine models to treat MC-38 tumor cells.  The results of this experiment show that the slow 
release Montanide solution with anti-CTLA-4 was effective in activating antitumor activity 
while minimizing autoimmune side effects6.  Both of these studies are unable to effectively 
eliminate the respective tumors completely5,6. 
 
In this study, we hypothesize that direct intratumoral injections of anti-CTLA-4 will prove more 
effective in restricting tumor growth.  Additionally, we believe that delivering this antibody 
intratumorally in a retentive vehicle will allow for a prolonged presence at the tumor site and will 
enhance the antitumor response.  We have also delivered anti-CTLA-4 in combination with 
interluekin-12 (IL-12) in a hydrogel intratumorally.  IL-12 is a pro-inflammatory cytokine 
produced by dendritic cells and macrophages.  Our lab has demonstrated the efficacy of IL-12 
delivered intratumorally in a chitosan hydrogel delivery vehicle.  Our lab has also demonstrated 
tumor rejection in mice previously treated with IL-12 in chitosan solution7.  Chitosan is a non-
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toxic, biodegradable polysaccharide which can be derived from the exoskeletons of shellfish7.  
We believe that the combination therapy will inhibit the growth of pancreatic tumors while the 
IL-12 component will provide an additional level of immune activation. 
 
The goal of this study is to determine the effectiveness of anti-CTLA-4 as a potential 
immunotherapy when injected intratumorally in concert with IL-12 in a slow release controlled 
hydrogel.  The lower dose of intratumoral delivery not only will reduce autoimmune side effects, 
but also reduce cost for the patient.  Ipilimumab treatment currently costs $120,000 for a four 
dose injection schedule8.  By demonstrating that local delivery is just as effective in eliminating 
tumors, Ipilimumab treatment could be administered at lower doses and thus lower costs. 
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2. Materials and Methods  
2.1 Cell Line Preparation and Maintenance 
The Panc02 cell line was thawed from liquid nitrogen storage.  Panc02 cells were then cultured 
in a T-25 culture flask with McCoy’s 5A media supplemented with 10% fetal bovine serum and 
antibiotics at 37°C and 5% CO2.  Cells were passaged twice weekly or once 80%-90% 
confluency was reached in the flask.  One week prior to beginning of animal studies, cell culture 
would be expanded into a T-75 culture flask to ensure sufficient cell numbers.  Panc02 cells were 
counted using a 1:10 dilution of cell suspension and Trypan Blue.  The mixture would then be 
placed onto a hemocytometer for cell counting.  The four corner squares of the hemocytometer 
were used for cell counts.  Final cell number calculations are as follows in Equation 1. 
                                                      !"##$%& = !"##$	)*+,-"./ ∗ 10 ∗ 10/                            (Equation 1) 
Viable cells counted did not take up the Typan Blue stain and cells overlapping only the top and 
left boundaries of a square were included in the count.  Panc02 cells were passaged at a dilution 
of 1:10 in a new T-25 culture flask. 
2.2 Inoculation and Tumor Measurements 
For tumor inoculation, all mice were anesthetized by administering a 50 µL intraperitoneal 
injection of 1:1:4.6 mixture of Ketamine, Xylazine, and deionized water, respectively.  Mice in 
each study were given 2.5×107 Panc02 cells in 100 µL of PBS subcutaneously to the shaven 
right flank on day 0.  After formation of palpable tumors, usually day 5 after implantation, 
treatment regime began.  All intratumoral injections that were given were administered in a 
subcutaneous fashion, however, treatment was injected once syringe needle penetrated the tumor.  
In all experiments, two-week old female C57BL/6J mice were ordered from Jackson 
Laboratories for use.  Tumor measurements and examination of health were made twice weekly.  
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Tumors were measured in two dimensions and the following equation was used when calculating 
volume: 
                                                                  𝑉 = 9: 𝑙$<*=-: 𝑙#*,>                                        (Equation 2) 
The previous equation does assume the tumors are of ellipsoid shape.  Mice were sacrificed by 
cervical dislocation after tumor volumes eclipsed 1000 mm3.  Anti-CTLA-4 antibody (clone 
9D9) was ordered from Bio X Cell.   
2.3 Pilot Study 
In the initial pilot study to investigate the antitumor activity of anti-CTLA-4, two groups of five 
mice were used.  Treatments began on day 5 after implantation and repeated on days 8 and 11 
and given twice weekly until the conclusion of the experiment.  Control mice were given PBS in 
50 µL.  Antibody treatment group was administered at 30 µg of antibody in 50 µL of PBS 
solution. 
2.4 Dosing Study 
The dosing study was expanded to four treatment groups.  Intratumoral treatments occurred on 
days 5, 8, and 11.  The control group of 3 mice was given 50 µL of PBS.  The next group was 
given 30 µg of anti-CTLA-4 in 50 µL of solution to four mice.  Five mice participated in both the 
60 µg and 120 µg groups. 
2.5 Chitosan Co-Formulation 
In the first co-formulation study, five mice per group were used.  This study consisted of three 
groups of mice: A control, anti-CTLA-4 only, and anti-CTLA-4 co-formulated with a chitosan 
hydrogel.  Treatments were administered on days 5, 12, and 19.  Again, control group mice were 
administered intratumoral PBS injections.  Anti-CTLA-4 only mice received a 60 µg treatment 
and finally anti-CTLA-4 co-formulated with chitosan received a 50 µL intratumoral injection of 
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a chitosan hydrogel and 60 µg of anti-CTLA-4. The chitosan hydrogel was prepared by 
dissolving purified lyophilized chitosan in PBS to 1% weight by weight.  Anti-CTLA-4 was then 
added to appropriate concentration. 
2.6 Combination Immunotherapy 
In the final study, six groups of 5 mice were used to investigate the effects of combination 
immunotherapy of anti-CTLA-4 and IL-12.  Again, a control group consisting of 5 mice were 
administered 50 µL of PBS intratumorally.  Intraperitoneal injections of 60 µg of anti-CTLA-4 
were given to the next group.  An additional group new to any of the studies was a hydrogel only 
group.  50 µL of hydrogel was administered intratumorally to mice.  Additionally, a group 60 µg 
of anti-CTLA-4/hydrogel and a group of 1 µg of IL-12/hydrogel were given intratumoral 
injections.  Finally, a combination group of 60 µg of anti-CTLA-4, 1 µg of IL-12, and hydrogel 
were delivered intratumorally in combination.  Treatments were given on days 7, 14, and 21 or 
once weekly due to the retention of the hydrogel.  This was done to ensure accurate tumor 
measurements. 
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3. Results 
3.1 Demonstration of Efficacy 
Since anti-CTLA-4 is new to our lab, a pilot study was performed to demonstrate the efficacy of 
anti-CTLA-4 treatment.  After conclusion of the study, growth curves (Figure 1A) and average 
tumor volumes (Figure 1B) were constructed between the two groups: anti-CTLA-4 treated and 
untreated. 
	
Figure 1: Tumor growths from initial pilot study of anti-CTLA-4 efficacy.  n=4 
	
Mice from the study were sacrificed on day 41 as tumor volumes had eclipsed 1000 mm3 for the 
untreated group and the treated group approached that threshold.  Additionally, anti-CTLA-4 
treated mice had shown signs of minimal dermatitis.  None of the mice exhibited any weakness 
or abnormal behavior.  From Figure 1, the untreated group had an average tumor volume of 1364 
mm3 and the anti-CTLA-4 treated group showed reduced average tumor size of 960 mm3.  The 
standard deviations of the groups were: 412 mm3 for the untreated group and 671 mm3 for the 
anti-CTLA-4 treated group.  Individual growth curves were also generated but are not shown 
here. 
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3.2 Anti-CTLA-4 Dosing Study 
Following the pilot study, our lab was confident that anti-CTLA-4 had some antitumor efficacy.  
Because it was our first time using anti-CTLA-4, a dosing study was needed to determine the 
optimal dose.  Previous studies that had delivered anti-CTLA-4 locally used doses ranging from 
30 µg to 90 µg and used a dose of 200 µg of anti-CTLA-4 for systemic (intraperitoneal) 
injections.  However, the study was not delivered directly into the tumor.  Therefore, the dosing 
study consisted of four groups: a control (PBS), a 30 µg group, a 60 µg group, and a 120 µg 
group.  Results from the dosing study are shown below in Figure 2. 
	
Figure 2: Growth curve of dosing study.  Groups were given bi-weekly injections. n=3-5 
All remaining mice were sacrificed on day 46 at the conclusion of the study.  On day 17, a 
mouse in the PBS group was accidentally killed due to a bad injection resulting in an air 
embolism.  The PBS group, as expected, had the highest average tumor volume at the conclusion 
of the study with an average size of 1311 mm3.  The 120 µg group had an average tumor size of 
839 mm3 followed by the 30 µg group at 609 mm3.  The 60 µg group yielded the smallest 
average tumor size at 304 mm3, over half that size of the next closest group.  Standard deviations 
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were 31.66 mm3, 429 mm3, 389 mm3, and 587 mm3 for the PBS, 30 µg, 60 µg, and 120 µg 
groups, respectively. 
 
3.3 Co-Formulation of Anti-CTLA-4 with Chitosan 
After determining that an optimal intratumoral dose of anti-CTLA-4 was 60 µg, formulation of 
the antibody with chitosan was investigated.  Previous studies had used a Montanide emulsion as 
a delivery vehicle for anti-CTLA-4.  However, this solution was delivered subcutaneously as 
opposed to intratumorally.  Our lab has previously demonstrated that chitosan leads to increased 
retention at the tumor site7.  The 60 µg dose was combined with a chitosan hydrogel and injected 
intratumorally.  From the measurements the average and individual growth curves generated are 
shown in Figure 3 and 4.   
	
Figure 3: Individual growth curves of treatment groups.  n=5 
	
From these results, the anti-CTLA-4/chitosan treated group showed the smallest sized tumors.  
This group was the only to have at least one mouse eliminate its tumor.  Earlier in the study at 
day 23, 60% of the anti-CTLA-4/chitosan group did not have any palpable tumor mass.  Anti-
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CTLA-4 treatment still shows to restrain tumor growth when compared to PBS treated mice.  
The average tumor volumes between groups were calculated and shown in Figure 4. 
	
Figure 4: Average tumor volume by group. n=5 
	
The average tumor size for the PBS mice once again eclipsed the 1000 mm3 barrier with the final 
average tumor size of 1021 mm3.  The 60 µg anti-CTLA-4 only group had a final average tumor 
volume of 763 mm3 while the 60 µg anti-CTLA-4/chitosan group had the lowest tumor sizes at 
an average of 407 mm3.  It is important to note that one mouse from the co-formulated group 
eliminated its tumor and two additional mice were lacking tumors until day 23 and day 42 of the 
50 day study.  The mice were examined periodically during the study and all mice seemed to be 
free of dermatitis and abnormal behavior.  The co-formulation group did develop sores at the 
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tumor site after injections that eventually healed.  Selected mice from each group are shown 
below in Figure 5. 
	
Figure 5: Selected mice from day 18.  A: PBS Group B: Anti-CTLA-4 C: Anti-CTLA-4/Chitosan 
	
From Figure 5c the sores that were mentioned previously can be faintly seen as a scab.  This 
severity of sore was representative of the group, however, bleeding was recorded in one of the 
mice.  Overall, the results from this study supported initial hypothesis. 
 
3.4 Combination Therapy of Anti-CTLA-4 and IL-12 in a Novel Hydrogel 
From the conclusion of the previous study, further investigation into hydrogel delivery was 
needed.  Our lab has developed a novel controlled release hydrogel.  We wanted to utilize this 
hydrogel to deliver anti-CTLA-4.  Additionally, we wanted to initiate a combination study 
including IL-12 and anti-CTLA-4 delivered in the gel.  In Figure 6, growth curves are shown.  
This study was actually repeated as the first attempt was done with mice that already had severe 
dermatitis.  Initially, we proceeded to run the experiment in hopes that the mice would recover 
from their skin condition.  Over the course of the experiment the mice were monitored 
extensively and never regained normal skin health.  By day 14, the mice had scabbing from dry, 
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irritated skin and the control mice did not grow tumors at the same rate as we had seen before.  
Therefore, we decided to improve on the experiment by performing it again with healthier mice 
and additional groups so as to measure the effects of the gel alone.   
	
Figure	6:	Growth	curves	from	the	Combination	Immunotherapy	study.		n=5	
	
The most notable result of this study is that after 44 days, the combination group had no 
detectable tumor mass.  In addition, the IL-12/Gel group performed similarly but had one mouse 
develop and sustain a very small tumor.  Average tumor volumes for the PBS, intraperitoneal 
anti-CTLA-4, Gel only, anti-CTLA-4/Gel were 715 mm3, 477 mm3, 1065 mm3, and 911 mm3, 
respectively.   
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Figure	7:	Individual	growth	curves	for	all	treatment	groups	participating	in	the	combination	immunotherapy	study. 
 
Figure 7 shows the individual growth curves of the mice participating in the combination study.  
The group administered anti-CTLA-4 alone, intraperitoneally, developed severe dermatitis and 
loss most of their fur coat two weeks into the study.   
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4. Discussion 
4.1 Demonstration of Efficacy 
The efficacy of anti-CTLA-4 has been shown to be dependent on whether or not tumor invading 
myeloid cells are present.  The effects of these myeloid cells are that FcγR crosslinking occurs 
which results in the cytolytic degradation of regulatory T cells that express CTLA-4.  Since 
pancreatic adenocarcinoma is known to have abundant myeloid cell invading activity, it is 
possible that the Panc02 cell line would respond promisingly to CTLA-4 blockade9.  The results 
from this quick pilot study confirmed the antitumor activity associated with anti-CTLA-4.  The 
bi-weekly injections allowed for anti-CTLA-4 to maintain the blockade over a longer duration 
and to replenish antibody concentrations after clearance of the first dose.  The lower average 
tumor size confirms that anti-CTLA-4 has potential in restricting tumor size in the Panc02 cell 
line.  The current standard of Ipilimumab treatment for patients is by systemic route, however 
many patients experience autoimmune side effects like dermatitis4.  It is possible that if the cause 
of these adverse side effects are the reduction of regulatory T cells, a local and controlled release 
delivery method could potentially limit these side effects. 
4.2 Anti-CTLA-4 Dosing Study 
Results from the dosing study were surprising in that the highest dosage group, 120 µg, had the 
highest tumor volumes when compared to the other anti-CTLA-4 treatment groups.  From 
previous studies, local delivery at 60 µg was delivered peritumorally.  This reaffirmed the 
decision that the 60 µg dose would be optimal moving forward with future experiments.  It was 
unexpected that the highest dosage group, 120 µg of anti-CTLA-4, failed to restrain tumor 
growth and ranked last among treatment groups for tumor size.  The initial hypothesis was that 
the higher dose would have a greater and more intense effect intratumorally.  A similar 
17	
	
phenomena was observed in Sandin et al., where treatment frequency and dosage was analyzed 
in their study.  Their findings included an increase in the levels of regulatory T cells found in the 
serum of the mice treated with higher doses of CTLA-4 blockade.  A possible explanation in this 
finding was a suppression assay performed by Sandin et al. finding that regulatory T cells have 
the potential to down regulate the proliferation of responder cells and thus lower immune 
response in the tumor environment5.  In Sandin et al., where treatments were given 
peritumorally, our study wanted to investigate the enhanced effects of direct intratumoral 
delivery5.  We hypothesized that due to pancreatic tumors having a thick fibrotic stroma, local 
injections near the tumor may not have the same effect as drug permeability at the stroma by 
administering the treatments directly into tumors10. 
4.3 Co-Formulation of Anti-CTLA-4 with Chitosan 
This study returned promising results as during the treatment scheduling, the mice treated with 
the co-formulated gel showed almost no tumor growth.  Two mice eliminated their tumors 
during the treatment regime however once the treatments were terminated, a tumor in one of the 
mouse began to grow rapidly.  The administered chitosan hydrogel was noted and physically 
detected in the flanks of the mice up to 6 days following the treatment.  This indicates that the 
chitosan was able to maintain a sustained delivery of anti-CTLA-4 for an extended period of 
time.  However, sores and ulcers did develop right at the tumor sites for the groups treated with 
the hydrogel.  It is possible that the intensity of the immune response to the anti-CTLA-4 
administration could have caused the ulceration.  We hypothesize that the prolonged sustained 
delivery correlates to an increase in antitumor activity.  When compared to a study done by 
Sandin et al., tumor growth showed to only be restrained in groups treated peritumorally with 
anti-CTLA-4 against Panc02 tumors even with increased treatment days while when delivered in 
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a chitosan hydrogel intratumorally, tumor growth would cease in mice and in some cases 
completely regress as long as the treatments were delivered5.  A study performed by Fransen et 
al. showed that the delivery of anti-CTLA-4 in a slow release Montanide emulsion 
subcutaneously only restrained tumor growth in MC-38 tumors expressing ovalbumin6.  While 
the tumor is different from the Panc02 cell line used in this study, we are still able to demonstrate 
that intratumoral delivery is slightly more effective in that the average tumor volumes for the 
study performed by Fransen et al. were just short of 200 mm3 on day 35 while our study showed 
that in the same time frame, average tumor volumes were 109 mm3 with two mice completely 
lacking tumors.  One of the major critiques we had for this experiment was that there was no 
group to test the effects of the chitosan hydrogel on tumor growth.  Chitosan has been shown to 
have some biological activity therefore, the study needed to examine the effects of a chitosan 
hydrogel on pancreatic tumor growth11.  Also of note, in Sandin et al., their findings show that 
additional treatment frequency does not influence the growth of the tumor5.  Our findings in this 
study contradict that claim.  Mice treated with the co-formulation of anti-CTLA-4 and chitosan 
had no detectable tumor mass in 4 of the 5 mice, however after administration of the last dose on 
day 19, tumors began to grow.  This slow release of anti-CTLA-4 in the tumor may cause a 
constant immune response that may be more effective than a single dose that may be cleared 
from the system in as little as twenty four hours.   
4.4 Combination Therapy of Anti-CTLA-4 and IL-12 in a Novel Hydrogel 
The results of the combination study show that the combination of anti-CTLA-4, IL-12, and a 
hydrogel provided complete response in all mice treated.  Five out of five mice were completely 
cured of any palpable tumor mass in the combinatory group even after treatments were 
terminated.  These are slightly better results than with the IL-12/Gel group in which all but one 
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mouse completely responded.  Our lab has demonstrated similar results in mice using IL-12 and 
a chitosan based hydrogel7.  Figure 7 shows the individual growth curves of the IL-12/Gel group 
and it is notable that the one mouse that developed a tumor maintained a relatively consistent 
mass and behaves benign.  In addition to the tumor growing at a slow rate, it is relatively small.  
Our results also show that the gel group performed similar to the control, however the average 
tumor volume in the Gel Only group was greater than that of the control treated with PBS.  
Furthermore, the anti-CTLA-4/gel treated group had very large tumors.  This may provide some 
support about the dosing of anti-CTLA-4.  The immune response that was induced in the anti-
CTLA-4/gel group could have been so great that regulatory T cells could have been recruited to 
the site and suppressed the immune response5.  Nonetheless, as far as efficacy goes, this study 
does demonstrate that IL-12 is more effective in treated pancreatic tumors as it showed to much 
less toxic and had a complete response rate of 80%.  However, local delivery of anti-CTLA-4 
confirmed its toxicity and ability to induce adverse autoimmune related side effects when 
delivered systemically.  All five mice in the intraperitoneal injection group had varying levels of 
dermatitis and displayed ill behaviors while most of the anti-CTLA-4 groups treated 
intratumorally sustained minor ulceration at the tumor site. 
4.5 Future Direction 
Following the conclusion of the combination study, rechallenge studies will be performed to see 
if any cured mice have retained immunity against Panc02.  Our lab has previously shown mice 
treated and cured with IL-12 and chitosan maintain immunity against the rechallenged cell lines7.  
We hypothesize that with the addition of IL-12 in the hydrogel treatments, some of these mice 
will have immunity when rechallenged on the left flank.  Additionally, serum analysis should be 
performed in order to investigate anti-CTLA-4 blood concentration of dose levels of anti-CTLA-
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4 when delivered in a hydrogel vehicle.  Additionally, it has already been shown that patients 
receiving anti-CTLA-4 intravenously show increased regulatory T cell concentrations12.  
Therefore, seeing the effect of regulatory T cell levels in response to treatment with a hydrogel 
and having a prolonged immune response should be investigated in order to determine more 
appropriate doses for these delivery vehicles.  	
 
5. Conclusions 
In conclusion, anti-CTLA-4 is a promising drug belonging to a class of therapeutics that has 
potential to revolutionize cancer treatments.  The toxicity of anti-CTLA-4 is quite evident by the 
murine models we have used and more work should be done in order to reduce the toxicity levels 
such as delivery method.  In this study, we have shown that a lower dose of anti-CTLA-4 is more 
effective in restraining tumor growth than when compared to a systemic delivery method.  Not 
only is the antitumor activity treated in mice equal and perhaps more effective in the locally 
delivered groups when compared to the systemic group, but the mice treated locally also showed 
much milder side effects as a result of the treatment.  Ulceration was the most common side 
effect in the mice treated locally.  When compared to IL-12, anti-CTLA-4 performs much worse 
when delivered in a hydrogel based delivery vehicle.  As the results show, the IL-12 group was 
much more effective in eradicating tumors whereas, anti-CTLA-4 in hydrogel could only restrain 
growth for a short period.  Additionally, tumors that are more difficult to access would be able to 
be delivered with image guided and stereotactic injections.  For tumors that are readily 
accessible, treatment is very favorable as the treatment can be made and injected bedside.  The 
future of anti-CTLA-4 therapy to treat tumors may be dependent on how well the toxicity and 
side effects of the drug can be managed. 
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